Laurus Labs Limited (NSE:LAURUSLABS)

Market Cap	1.03T +113.1%
Revenue (ttm)	72.70B +22.6%
Net Income	10.93B +114.9%
EPS	20.23 +114.1%
Shares Out	540.31M
PE Ratio	94.20
Forward PE	73.32
Dividend	2.40 (0.13%)
Ex-Dividend Date	May 8, 2026

Volume	1,645,038
Open	1,898.00
Previous Close	1,905.50
Day's Range	1,894.80 - 1,964.50
52-Week Range	823.10 - 1,981.80
Beta	0.36
Analysts	Hold
Price Target	1,561.38 (-19.85%)
Earnings Date	Oct 28, 2026

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 7,059
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LAURUSLABS

Financial Performance

In fiscal year 2026, Laurus Labs's revenue was 68.13 billion, an increase of 22.67% compared to the previous year's 55.54 billion. Earnings were 8.89 billion, an increase of 148.04%.

Analyst Summary

According to 14 analysts, the average rating for LAURUSLABS stock is "Hold." The 12-month stock price target is ₹1,561, which is a decrease of -19.85% from the latest price.

Price Target

₹1,561

(-19.85% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error